Panacea Analysis
What is Panacea?
Panacea provides FDA regulatory consulting for life sciences companies across 510(k), De Novo, PMA, IND, NDA, and BLA pathways. The company combines an ex-FDA regulatory team with an in-house AI platform and uses fixed, milestone-based pricing instead of hourly billing. Its site claims decades of combined experience, hundreds of successful submissions, and faster client delivery through AI support.
Location
San Francisco, United States
Employees
1-10
Founded
2026
Industry
Healthcare, Healthcare Services
AI Pattern
AI-native application
Blog Category
Health
Builds Hardware
Software only
Business Model v4
AI-native service
Delivery Model
Services-as-software (AI-native service)
Sub-cluster
regulatory submission tools
YC Partner
Aaron Epstein
Product Description
Panacea specializes in FDA regulatory consulting, offering a range of services designed to assist life sciences companies, particularly startups in the medical device and pharmaceutical sectors, in navigating the FDA approval process. Their main product offerings include:
-
FDA Regulatory Consulting: Leveraging a team of ex-FDA experts, Panacea provides strategic guidance to clients, helping them define optimal regulatory pathways and develop milestone-driven plans.
-
AI-Driven Regulatory Submission Tools: The company utilizes an AI platform to accelerate the regulatory submission process, aiming to reduce approval timelines by 50%.
-
Comprehensive Support: Panacea offers full support from pre-FDA meetings through to final submission, ensuring that clients are well-prepared at every stage of the approval process.
-
Fixed, Risk-Free Pricing: Their pricing model is based on completed milestones rather than hourly billing, which aligns incentives and provides clients with predictable costs.
Key benefits of Panacea's offerings include reduced timelines for FDA approval, expert-led strategic planning, and a risk-free pricing structure that enhances client confidence.
See something that needs updating? Suggest edits to this profile.